Recently, in the CLARINET trial, lanreotide 120 mg Autogel was established for its anti tumoral effect in both pancreatic and gastroenteric locally advanced or metastatic neuroendocrine tumors with Ki-67 up to 10 %. Here, MKI67 is linked to neuroendocrine neoplasm.